FLGT vs. LFST, WGS, VCYT, ARDT, ADUS, PGNY, NHC, PACS, GRAL, and AHCO
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include LifeStance Health Group (LFST), GeneDx (WGS), Veracyte (VCYT), Ardent Health Partners (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), National HealthCare (NHC), PACS Group (PACS), Grail (GRAL), and AdaptHealth (AHCO). These companies are all part of the "healthcare" industry.
Fulgent Genetics vs. Its Competitors
Fulgent Genetics (NASDAQ:FLGT) and LifeStance Health Group (NASDAQ:LFST) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
In the previous week, Fulgent Genetics and Fulgent Genetics both had 5 articles in the media. LifeStance Health Group's average media sentiment score of 1.02 beat Fulgent Genetics' score of 0.18 indicating that LifeStance Health Group is being referred to more favorably in the news media.
Fulgent Genetics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Fulgent Genetics received 229 more outperform votes than LifeStance Health Group when rated by MarketBeat users. Likewise, 59.76% of users gave Fulgent Genetics an outperform vote while only 34.04% of users gave LifeStance Health Group an outperform vote.
Fulgent Genetics has higher earnings, but lower revenue than LifeStance Health Group. LifeStance Health Group is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.
48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 31.8% of Fulgent Genetics shares are held by insiders. Comparatively, 3.2% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Fulgent Genetics presently has a consensus target price of $24.00, suggesting a potential upside of 14.34%. LifeStance Health Group has a consensus target price of $8.50, suggesting a potential upside of 56.83%. Given LifeStance Health Group's stronger consensus rating and higher possible upside, analysts clearly believe LifeStance Health Group is more favorable than Fulgent Genetics.
LifeStance Health Group has a net margin of -7.90% compared to Fulgent Genetics' net margin of -59.39%. Fulgent Genetics' return on equity of -1.81% beat LifeStance Health Group's return on equity.
Summary
LifeStance Health Group beats Fulgent Genetics on 10 of the 18 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:FLGT) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy FLGT Stock Free FLGT Stock Alerts